Gene expression profiles in liver cancer

DETAILED DESCRIPTION 1.
A method of diagnosing hepatocellular carcinoma in a human patient, compnsing: (a) detecting the level of expression in a tissue sample of ten or more genes from Tables 3A, 3B, 5, 7A, 7B, 8A, and 8B; wherein differential expression of the genes in Tables 3A, 3B, 5, 7A, 7B, 8A, and 8B is indicative of hepatocellular carcinoma.
2.
A method of detecting the progression of hepatocellular carcinoma in a human patient, comprising: (a) detecting the level of expression in a tissue sample of ten or more genes from Tables 3A, 3B, 5, 7A, 7B, 8A, and 8B; wherein differential expression of the genes in Tables 3A, 3B, 5, 7A, 7B, 8A, and 8B is indicative of hepatocellular carcinoma progression.
3.
A method of monitoring the treatment of a human patient with hepatocellular carcinoma, comprising: (a) administering a pharmaceutical composition to the patient; (b) detecting the level of expression of ten or more genes from Tables 3A, 3B, 5, 7A, 7B 8A and 8B from a cell or tissue sample from the patient; and (c) comparing the patient gene expression detected in step (b) to gene expression from a cell population comprising normal liver cells or to gene expression from a cell population comprising hepatocellular carcinoma cells or both.
4.
A method of diagnosing a metastatic liver cancer in a human patient, comprising: (a) detecting the level of expression in a tissue sample of ten or more genes from Tables 4A, 4B, 5, 6A, 6B, 9A and 9B; wherein differential expression of the genes in Tables 4A, 4B, 5, 6A, 6B, 9A, and 9B is indicative of metastatic liver cancer.
5.
A method of detecting the progression of a metastatic liver cancer in a human patient, comprising: (a) detecting the level of expression in a tissue sample of ten or more genes from Tables 4A, 4B, 5, 6A, 6B, 9A and 9B; wherein differential expression of the genes in Tables 4A, 4B, 5, 6A, 6B, 9A, and 9B is indicative of metastatic liver cancer progression.
6.
A method of monitoring the treatment of a human patient with metastatic liver cancer, comprising: (a) administering a pharmaceutical composition to the patient; (b) detecting the level of expression of ten or more genes from Tables 4A, 4B, 5, 6A, 6B, 9A and 9B from a cell or tissue sample from the patient; and (c) comparing the patient gene expression detected in step (b) to gene expression from a cell population comprising normal liver cells or to gene expression from a cell population comprising metastatic liver tumor cells or both